AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03237819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfate, Magnesium
Description: Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.~For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)
Study NCT03237819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
Study NCT01000337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
Study NCT01000337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
Study NCT03239132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath-based meditation
Description: The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
Study NCT03239132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation educational materials
Description: Meditation educational materials
Study NCT03239132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation educational materials
Description: Meditation educational materials
Study NCT01273181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes
Study NCT01273181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg every 8 hours for a maximum of 15 doses
Study NCT01273181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
Study NCT01273181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
Study NCT01723995 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: low-level laser on nipples
Description: The LASER HAND WL device, manufactured by MM Optics.
Study NCT01723995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-level laser on nipples
Description: The LASER HAND WL device, manufactured by MM Optics.
Study NCT00527423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF Trap Eye
Description: Intravitreal injection
Study NCT04026126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat Therapy Treatment
Description: Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
Study NCT02645526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Woolen cap
Study NCT02918994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LearningRx cognitive training
Description: A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
Study NCT02754401 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 16 Items
Description: Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).
Study NCT02754401 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PSI
Description: The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
Study NCT04090086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
Study NCT04090086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
Study NCT06364722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
Study NCT06364722 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
Study NCT04892979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise (centre-based)
Description: Depending on the preference of participants, they can either choose to join three 60-minute centre-based sessions plus two sessions of 30-minute home exercise per week, or two 60-minute centre-based sessions plus four sessions of 30-minute home exercise per week. Each session will include warm-up and cool-down exercises, aerobic exercises, and progressive strengthening exercises prescribed based on individual ability (Table 1). Aerobic exercises will be performed at 60-75% (up to 85% for fit individuals) of the predicted maximum heart rate. The respective rate of perceived exertion during exercise will be maintained between 4 and 6 out of 10 on the Borg CR scale \[10\], indicating moderate to strenuous exercise levels. Additionally, physiotherapists will provide education related to COVID-19, energy conservation, and stress management during the program.
Study NCT04892979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise (online-based)
Description: Participants in the OBR group will attend one face-to-face session to learn how to use a mobile application (app) followed by 6 weeks of home exercises. The online treatments will be delivered via the Caspar Health e-system, a German-designed Internet-based system, is available for desktop PCs and as a mobile app for both iOS and Android smartphones. This system will enable patients to follow their therapists' treatment plans in an asynchronous manner. The OBR programme will last for 6 weeks. Participants will be instructed to perform 40 minutes of structured exercises 6 times per week. In the first week, six 40-minute online exercise sessions will be delivered through push notifications on the mobile app.
Study NCT01492361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101
Description: Parallel Assignment
Study NCT01492361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment
Study NCT01492361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin therapy
Description: Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C >40 mg/dL and ≤100 mg/dL)
Study NCT01492361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin therapy
Description: Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C >40 mg/dL and ≤100 mg/dL)
Study NCT04375293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiome swabs
Description: Swabs for analysis of microbiome
Study NCT04375293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome swabs
Description: Swabs for analysis of microbiome
Study NCT04375293 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Microbiome swabs
Description: Swabs for analysis of microbiome
Study NCT00977288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: 10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Study NCT00977288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: atorvastatin
Description: atorvastatin tablet, 10mg, once daily for 8 weeks
Study NCT00977288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: atorvastatin
Description: atorvastatin tablet, 10mg, once daily for 8 weeks
Study NCT00977288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet, once daily for 8 weeks
Study NCT00977288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablet, once daily for 8 weeks
Study NCT03858712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Care Team Alert
Description: 2) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher).
Study NCT03858712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive Care Team Alert
Description: Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy.
Study NCT01653665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leukine
Description: Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
Study NCT01653665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
Study NCT04613830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride
Study NCT04613830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol hydrochloride
Description: Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
Study NCT05390346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: The intervention programs consist of nutrition monitoring and diet intervention.
Study NCT02624843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzyl Alcohol Lotion 5%
Description: White topical lotion
Study NCT02624843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulesfia (benzyl alcohol lotion) 5%
Description: White topical lotion
Study NCT02624843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White topical lotion
Study NCT01717976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DISPO ED
Description: primary care based nurse telephone support
Study NCT02402166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489
Description: All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
Study NCT00676871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
Study NCT00676871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
Study NCT00676871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
Study NCT00676871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
Study NCT00676871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
Study NCT00676871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
Study NCT00676871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
Study NCT03312257 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multifocal D +2.50 add & 0.01% atropine
Description: Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
Study NCT02972398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
Study NCT02972398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator of N-acetylcysteine
Description: Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
Study NCT03089112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607
Description: Take it once per period
Study NCT03089112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1501
Description: Take it once per period
Study NCT03089112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1607+HGP1501
Description: Take it once per period
Study NCT04799600 — intervention group
Intervention type: OTHER
Intervention: BRESCİA-COVİD Respiratory Severity Scale
Description: KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score
Study NCT00719966 — intervention group
Intervention type: DRUG
Intervention: anastrozole
Description: Patients receive aromatase inhibition therapy.
Study NCT00719966 — intervention group
Intervention type: DRUG
Intervention: exemestane
Description: Patients receive aromatase inhibition therapy.
Study NCT00719966 — intervention group
Intervention type: DRUG
Intervention: letrozole
Description: Patients receive aromatase inhibition therapy.
Study NCT00719966 — intervention group
Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: Endothelial function is measured
Study NCT03165448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-operative USOS scale testing
Description: Patient has to self-report USOS questionnaire just before the procedure as main scale.
Study NCT03165448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-operative SDPQ, MDAS and VAS testing
Description: Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
Study NCT03165448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Post-operative doctor's reported USOS
Description: Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
Study NCT03165448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Re-testing 4-6 weeks later
Description: All the participants has to refill USOS questionnaire 4-6 weeks later.
Study NCT02153398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 10 mg
Study NCT02153398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 10mg
Study NCT02153398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 20 mg
Study NCT02497456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up counselling
Study NCT03044548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive supervision
Description:  Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle .
Study NCT01345019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 4 weeks.
Study NCT01345019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Administered by intravenous infusion over 15 minutes once every 4 weeks
Study NCT01345019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection once every 4 weeks.
Study NCT01345019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zoledronic acid
Description: Administered by intravenous infusion over 15 minutes once every 4 weeks
Study NCT01345019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (for the open-label treatment phase)
Description: Administered by subcutaneous injection once every 4 weeks.
Study NCT01345019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab (for the open-label treatment phase)
Description: Administered by subcutaneous injection once every 4 weeks.
Study NCT02204969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lithia water
Description: * Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~* Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels
Study NCT02204969 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic stimulation
Description: All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
Study NCT00219297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study NCT03273322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg qd
Description: 10mg qd
Study NCT03273322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg qd
Description: 15mg qd
Study NCT03273322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT
Description: Aspirin 75 mg qd + Clopidogrel 75 mg qd
Study NCT01799681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an 8-week blended indoor-outdoor exercise program
Description: stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
Study NCT01799681 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: an 8-week upper limb and hand exercise program
Description: upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy